Spermicidal and virucidal properties of various forms of sophorolipids

Abstract

A method for inactivating spermatozoa, neutralizing or inactivating a virus, and neutralizing or inactivating HIV using sophorolipids having spermicidal and/or antiviral properties produced by synthesizing the sophorolipid by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids compounds and non-lactonic sophorolipids compounds and utilizing the natural mixture as a spermicidal and/or antiviral agent, and/or separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction and utilizing the lactonic fraction and/or the non-lactonic fraction as an spermicidal and/or antiviral agent, and sophorolipid compounds for use as spermicidal and/or antiviral agents.

1 . A method for inactivating spermatozoa by treating the spermatozoa with an effective amount of a 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound. 
     
     
         2 . The method as claimed in  claim 1 , wherein the 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound is selected from the group consisting of:
 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate; 
 Hexyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; 
 Ethyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and 
 combinations thereof. 
 
     
     
         3 . The method as claimed in  claim 1 , wherein the sophorolipid compound is in the form selected from the group consisting of a gel, a film, a foam, a suppository, a pessary, a liposomic formulation, a liquid imbibed in a sponge, and a liquid being released from an intravaginal or intrauterine delivery system. 
     
     
         4 . The method as claimed in  claim 1 , further comprising combining the 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound with a spermicidal agent. 
     
     
         5 . A method for neutralizing or inactivating a virus by treating the virus with an effective amount of a 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound. 
     
     
         6 . The method as claimed in  claim 5 , wherein the 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound is selected from the group consisting of:
 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate; 
 Hexyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; 
 Ethyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and 
 combinations thereof. 
 
     
     
         7 . The method as claimed in  claim 5 , wherein the sophorolipid compound is in the form selected from the group consisting of a gel, a film, a foam, a suppository, a pessary, a liposomic formulation, a liquid imbibed in a sponge, and a liquid being released from an intravaginal or intrauterine delivery system. 
     
     
         8 . The method as claimed in  claim 4 , further comprising combining the 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound with an antiviral agent. 
     
     
         9 . A method for neutralizing or inactivating HIV by treating the HIV with an effective amount of a 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound. 
     
     
         10 . The method as claimed in  claim 9 , wherein the 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound is selected from the group consisting of:
 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate; 
 Hexyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; 
 Ethyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and 
 combinations thereof. 
 
     
     
         11 . The method as claimed in  claim 9 , wherein the sophorolipid compound is in the form selected from the group consisting of a gel, a film, a foam, a suppository, a pessary, a liposomic formulation, a liquid imbibed in a sponge, and a liquid being released from an intravaginal or intrauterine delivery system 
     
     
         12 . The method as claimed in  claim 9 , further comprising combining the 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound with an antiviral agent.